Alzheimer's Drug Delays Onset in Genetic Study
Tap title to read story
A small study involving individuals with genetic mutations predisposing them to Alzheimer's shows that the biologic drug gantenerumab may significantly delay the onset of symptoms when administered early and consistently for extended periods (up to eight years). The 22 participants who received the drug longest experienced a nearly 50% reduction in symptom risk. While promising, outside experts caution about the study's small size and lack of a placebo control group. Funding for the ongoing research is threatened, raising concerns about continued access to the drug and hindering further investigation.
JQJO Editorial Desk · Human reviewed · AI assisted. Report a correction.